ZappRx Expanding Partnership with PARx Solutions as Part of Their Growth into New Treatment Areas
BOSTON--(BUSINESS WIRE)--Jun 5, 2018--ZappRx, a healthcare technology company that reduces the administrative burden associated with prescribing specialty medications, today announced it has expanded its partnership with PARx Solutions, a leader in prior authorization services, to cover all treatment areas supported on the ZappRx platform. This is a significant step to enabling ZappRx’s capabilities across Gastroenterology, Rheumatology, and Neurology.
The prior authorization process, particularly within the specialty pharmaceutical market, is extremely complex and drawn out, often taking several weeks for approval from the time a prescription is written. With a mission to drastically shorten the prior authorization timeline, ZappRx first partnered with PARx in November of 2016 to automate the specialty drug prescribing and prior authorization process for its three main treatment areas: Pulmonary Arterial Hypertension (PAH), Idiopathic Pulmonary Fibrosis (IPF) and Cystic Fibrosis (CF). ZappRx leverages PARx services to alleviate the administrative burden for clinicians focused on the care of patients with these complex diseases. Patients are now able to receive approvals for these critical therapies in a matter of days versus weeks.
“Since the beginning of our partnership, ZappRx and PARx Solutions have been very complementary. We strongly value our partnership and believe that ZappRx offers specialty drug prescribers a comprehensive solution that makes it dramatically easier for physicians to combat and treat complex diseases,” said Dan Rubin, president and CEO at PARx Solutions. “Together, we have been tremendously successful within the PAH and CF fields, and we look forward to extending our joint solutions into new therapeutic categories, which will immediately and dramatically increase the number of lives we can positively impact.”
Without the ZappRx platform, physicians reported experiencing PA approval rates below 75 percent, according to the company’s pre-implementation survey. ZappRx provides physicians with a comprehensive digital solution for specialty prescribing and prior authorization, increasing the approval rate to 95 percent in a matter of days, not weeks, for complex conditions. PARx is an essential partner in attaining these results.
“The integration of PARx’s services into our platform has been seamless and proven to be extremely valuable for our customers. We are excited to be able to extend our partnership and subsequent impact,” said Zoë Barry, CEO and founder of ZappRx. “Today’s prior authorization process continues to be a burden on physicians who treat complex conditions like pulmonary arterial hypertension. By digitizing both the prescribing and prior authorization process for them under the umbrella of a single solution, we can significantly reduce clinician’s administrative burden, while also improving the quality of care they provide their patients.”
ZappRx users range from large academic medical centers to small, independent physician practices. Across the board, the combination of the two digital entities will empower providers with the tools they need to manage specialty prescription orders.
To learn more about ZappRx’s specialty prescribing platform please visit them online at www.zapprx.com.
To learn more about PARx Solutions, please visit the company online at www.parxsolutions.com.
About ZappRx ZappRx simplifies the complex process required to order specialty medications, making it easier to collect and save all of the information required to order a prescription — including pharmacy information, payer/prior authorization requirements, and relevant patient clinical history. ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for fax and phone call interactions. The platform is currently live in three disease areas, including Pulmonary Arterial Hypertension (PAH), Idiopathic Pulmonary Fibrosis (IPF), and Cystic Fibrosis, with plans to expand to support prescribing for other areas, including gastroenterology, rheumatology, neurology and oncology conditions.
About PARx Solutions The mission of PARx Solutions is to help patients get the medication that their physician believes is most appropriate for their condition. PARx fulfills this mission by helping prescribers overcome the cumbersome, frustrating and time-consuming challenges resulting from Prior Authorization requirements. Founded in 2008 and based in Burlington, Massachusetts, PARx Solutions has been successful in providing their PA system through physician offices across the nation. To date, tens of thousands of providers rely on PARx Solutions to process prior authorizations across multiple therapeutic areas.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180605005337/en/
CONTACT: Matter for ZappRx
Jessica Wolter, 978-518-4536
PARx Solutions Contact:
Warner Communications for PARx Solutions
Ariane Wolff, 978-729-3542
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: PRACTICE MANAGEMENT HEALTH PHARMACEUTICAL MANAGED CARE
Copyright Business Wire 2018.
PUB: 06/05/2018 08:03 AM/DISC: 06/05/2018 08:03 AM